---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-021978"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2025-07-02T23:59:59+00:00"
generated_at: "2026-05-18T09:35:12.351611+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Dyadic rebrands as Dyadic Applied BioSolutions; highlights $250K milestone & $1.5M Gates grant

## Summary
- Will do business as Dyadic Applied BioSolutions effective in 30 days; legal name unchanged.
- Reports $250,000 milestone payment for second non-animal dairy enzyme program.
- Received second $1.5M installment from $3.0M Gates Foundation grant for malaria/RSV mAbs.
- Company shifts from research-driven to commercially focused enterprise on non-therapeutic proteins.
- Targets commercialization of input proteins in 2025; C1 and Dapibus platforms are core.

## SEC filing metadata
- accession: 0001437749-25-021978
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2025-07-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000143774925021978/0001437749-25-021978-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000143774925021978/dyai20250702_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-021978
- JSON: https://secwatch.observer/filing/0001437749-25-021978.json
- Plain text: https://secwatch.observer/filing/0001437749-25-021978.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.